- Tumors726
- Pathology579
- Pathologic Processes568
- Nervous System Diseases489
- Nervous System Disorders463
Any
<10 miles
<30 miles
<50 miles
<70 miles
Filter Results
Condition
- Tumors726
- Pathology579
- Pathologic Processes568
- Nervous System Diseases489
- Nervous System Disorders463
Where are you looking?
How far are you willing to travel?Any
How old are you?
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
- HER2 negative
- PD-L1 positive
- ER positive
- HER2 positive
- EGFR negative
- EGFR positive
- PR positive
- ALK negative
- KRAS positive
- PD-L1 negative
- BRAF positive
- ER negative
- PR negative
- BRAF negative
- BRCA1 positive
- ROS1 negative
- BRCA2 positive
- p16 positive
- CD20 positive
- ALK positive
- HLA positive
- PIK3CA positive
- MET positive
- ROS1 positive
- HLA-A positive
- HR positive
- IDH negative
- MYC positive
- PALB2 positive
- TP53 positive
- p16 negative
- MET negative
- RET positive
- Anti-dsDNA positive
- BCR-ABL1 positive
- HBsAg positive
- NRAS positive
- RET negative
- TP53 negative
- ABCA4 positive
- ANA positive
- Bcl2 positive
- CCND1 positive
- CFTR positive
- HLA negative
- HLA-A negative
- HPV negative
- IDH positive
- KRAS negative
- MSS positive
- NTRK negative
- NTRK positive
- RAS positive
- RB1 negative
- RB1 positive
- dMMR positive
- APP positive
- BCL6 positive
- BRCA positive
- BRCA1 negative
- BRCA2 negative
- COL7A1 positive
- FMR1 positive
- MDM2 positive
- MGMT negative
- MSI-H positive
- NF1 positive
- PSEN1 positive
- PSEN2 positive
- PTEN positive
- Philadelphia chromosome positive
- RF positive
- RHO positive
- Ras negative
- TROP2 negative
- TROP2 positive
- ctDNA positive
- pMMR positive
- 11q negative
- 11q positive
- AKT negative
- ALPL positive
- ATM positive
- Aβ1-42 positive
- C5 positive
- CLDN18.2 positive
- DLL3 positive
- DMD positive
- EBV positive
- FOXO1 fusion negative
- GRN positive
- HBB positive
- HEXA positive
- HEXB positive
- HPV positive
- HPV16 positive
- HRAS positive
- IGHV positive
- JAK2 positive
- KIT positive
- MGMT positive
- MLH1 positive
- MMR positive
- MSH2 positive
- MSH6 positive
- MSI-H negative
- NF2 positive
- NRAS negative
- PDE6A positive
- PDE6B positive
- PIK3CA negative
- PIK3CD positive
- PIK3R1 positive
- PMM2 positive
- PMS2 positive
- PTCH1 positive
- PTEN negative
- PiZZ positive
- RAF positive
- SPINK5 positive
- T790M positive
- TTR positive
- anti-PLA2R positive
- anti-Ro autoantibodies positive
- anti-Ro/SSA positive
- anti-Sm positive
- anti-Smith positive
- dMMR negative
- t(11;14) positive
- 12 negative
- 12 positive
- 13q negative
- 13q positive
- 16p11.2 deletion positive
- 17p negative
- 17p positive
- 19q negative
- 19q positive
- 1p negative
- 1p positive
- 1p/19q co-deletion positive
- 1p/19q loss positive
- 1p36 deletion positive
- 46 XX karyotype positive
- 5q SMA positive
- 5q-autosomal recessive SMA positive
- AAVrh74 antibody titers negative
- ABL-class fusion positive
- ABL-class fusions positive
- ABO negative
- ABO positive
- ACVR1 positive
- AChR positive
- AChR-Ab positive
- ADAMTS-13 negative
- ADAMTS-13 positive
- AFP positive
- AKT positive
- AKT1 positive
- APOL1 positive
- Acetylcholine receptor antibody positive
- Anti-CCP-2 positive
- Anti-HBc IgM negative
- Anti-Ro/SS-A positive
- Anti-SSA (Ro) positive
- Anti-SSB (La) positive
- Anti-Smith antibodies positive
- Antinuclear antibody positive
- Aβ1-40 positive
- Aβ1-42/Aβ1-40 ratio positive
- B7-H6 positive
- BCL-6 positive
- BCR-ABL1 e13a2 positive
- BCR-ABL1 e14a2 positive
- BCR-ABL1 fusion positive
- BCR-ABL1IS positive
- BTK-C481 positive
- Bcl-2 positive
- C1-INH functional activity positive
- C1-INH positive
- C10orf2 positive
- C4 antigen level positive
- C5 p.Arg885Cys positive
- C5 p.Arg885His positive
- C9orf72 positive
- CAG expansion positive
- CAG repeat in HTT positive
- CASR positive
- CCND2 positive
- CCND3 positive
- CCNE1 positive
- CD123 positive
- CD19 positive
- CD20 negative
- CD25 positive
- CD30 negative
- CD30 positive
- CD4 count negative
- CD4 count positive
- CD4 negative
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Stage IV
- Stage III
- Stage II
- Stage I
- 1927nm Fractional Thulium Laser Treatment
- Adjuvant Therapy (except reconstruction)
- Anti-Seizure Medications (up to 2 types)
- Any Treatment for Pancreatic Cancer
- At least one prior tumor-directed therapy
- Avoidance of Activities That Cause Joint Pain
- Biologic Anti-Neoplastic Agent
- CD4+ > 350 cells/microliter for at least twelve months
- Cancer-Directed Surgery
- Cellular Therapies for ALS
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
3079 trials
Columbus, OH (<10 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial tests whether inclisiran injections can prevent serious heart problems in high-risk adults who haven't had a major heart event yet by lowering their cholesterol levels. Inclisiran is a long-acting treatment that significantly lowers cholesterol.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 2 & 3
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing an injectable medication called efgartigimod PH20 SC in people with certain muscle inflammation diseases. The goal is to see if it helps improve their condition by lowering harmful proteins in their blood. The study focuses on patients with specific subtypes of these diseases who often don't respond well to usual treatments. Efgartigimod was developed for autoimmune diseases and has been approved for treating a specific muscle condition in adults.
Columbus, OH (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial tests if adding a radioactive drug to standard hormone treatments can better treat men with advanced prostate cancer. The drug targets and kills cancer cells with radiation, while standard treatments block hormones that help cancer grow.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is comparing two different treatments for men with metastatic castration resistant prostate cancer who have previously been treated with an alternate androgen receptor downregulation therapy. The study will compare how well each treatment improves the participant's rPFS (progression free survival) or death.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial tests an inhaler with three medications to help people with severe asthma who don't respond well to usual treatments. The inhaler reduces inflammation, relaxes muscles around the airways, and keeps them open longer. The study aims to see if this combination is more effective and safe compared to other treatments.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial tests if injecting special cells from a patient's own fat can reduce pain and improve function in people with knee osteoarthritis. These cells have been investigated in various studies for their potential to treat knee osteoarthritis by reducing pain and improving function.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test a combination of drugs to see if they are effective in reducing the chance of cancer recurrence or developing new cancers.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial compares a new treatment, frexalimab, with an existing pill, teriflunomide, in adults aged 18-55 who have relapsing multiple sclerosis. The study aims to see if frexalimab can reduce the frequency of symptom relapses better than teriflunomide. Participants will be monitored over several years.
Efficacy & Safety Awards
Pivotal Trial
Get notified when new Vitiligo trials are postedWe'll send you an email whenever new trials are posted
Columbus, OH (<10 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will evaluate if the drug upadacitinib is safe and effective in treating vitiligo, a chronic autoimmune skin disease. 540 participants will be enrolled worldwide to receive either upadacitinib or a placebo in Period A, followed by upadacitinib in Period B.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new drug called TAK-279 to see if it can help people with moderate to severe plaque psoriasis. The study will compare TAK-279 to an existing treatment called apremilast, which is approved for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis. The goal is to find out if TAK-279 can better reduce the skin problems associated with this condition.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new medication called NMRA-335140 to see if it helps people with major depressive disorder. It includes participants who have no safety concerns. The medication aims to improve mood by affecting brain chemicals.
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new medication called NMRA 335140 to see if it can help people with Major Depressive Disorder feel less depressed. The study involves an initial evaluation and a treatment phase where participants will receive either the medication or an inactive substance. The medication likely works by changing brain chemicals that affect mood.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test a drug to see if it's safe and effective to treat a lung disease called Idiopathic Pulmonary Fibrosis.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a medication called Pegozafermin to see if it can lower high levels of fats in the blood in people with severe hypertriglyceridemia. These patients have very high triglyceride levels, which can lead to serious health issues. The medication aims to reduce these fat levels to improve their health.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial studied if digital therapies plus standard care can reduce symptoms of schizophrenia in teens & adults.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new diabetes medication called orforglipron to see if it is safer and more effective than insulin in people with type 2 diabetes who are overweight or obese and at higher risk for heart problems. The study will last several years and involve multiple visits.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing gotistobart, a new drug that helps the immune system fight advanced lung cancer in patients who haven't responded to other treatments. It works by blocking a protein that allows cancer cells to hide from the immune system.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Get notified when new Erosive Esophagitis trials are postedWe'll send you an email whenever new trials are posted
Columbus, OH (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial tests BLI5100, an oral medication, in patients with Erosive Esophagitis (EE). It aims to see if BLI5100 can heal the esophagus and maintain its healing.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a medication called ritlecitinib, which is taken as oral capsules. It aims to help adults and adolescents who have non-segmental vitiligo, a condition that causes skin to lose its color. The medication works by managing the immune system to stop the skin from losing its color.
Efficacy & Safety Awards
Pivotal Trial
1
2
3
…50